Stock A102460 REYON PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News REYON Pharmaceutical Co., Ltd.

Equities

A102460

KR7102460003

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
13,780 KRW +1.17% Intraday chart for REYON Pharmaceutical Co., Ltd. +4.47% -16.69%
Mar. 21 REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
REYON Pharmaceutical Co., Ltd. announced that it has received KRW 10 billion in funding
CI
REYON Pharmaceutical Co., Ltd. announced that it expects to receive KRW 10 billion in funding
CI
Tranche Update on REYON Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 6, 2018.
CI
REYON Pharmaceutical Co., Ltd.'s Equity Buyback announced on July 6, 2018 has expired with 240,840 shares, representing 1.44% for KRW 4,975.65 million.
CI
Tranche Update on REYON Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 6, 2018.
CI
REYON Pharmaceutical Co., Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.
CI
REYON Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
CI
REYON Pharmaceutical Co., Ltd. announced that it has received KRW 40 billion in funding from Mirae Asset Daewoo Co., Ltd., KDB Capital Corp., Eum Private Equity, Industrial Bank of Korea, Investment Arm
CI
REYON Pharmaceutical Co., Ltd. announced that it expects to receive KRW 40 billion in funding from Mirae Asset Daewoo Co., Ltd., KDB Capital Corp., Eum Private Equity, Industrial Bank of Korea, Investment Arm
CI
REYON Pharmaceutical Co., Ltd.(KOSE:A102460) added to MSCI Acwi + Frontier Markets(acwi Fm) All Cap Index
CI
REYON Pharmaceutical Co., Ltd.(KOSE:A102460) added to Russell Global Index
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A102460 Stock
  4. News REYON Pharmaceutical Co., Ltd.